Real-World check: is talzenna safe for advanced breast cancer?
NCT ID NCT04982848
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will track 600 people in Korea with advanced breast cancer who are already being prescribed Talzenna. Researchers will watch for side effects and see how well the drug works in everyday medical practice, not in a strict research setting. The goal is to confirm the drug's safety and effectiveness after it has been approved for use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Talzenna (talazoparib)
What this could lead to
If successful, this study will confirm that Talzenna is safe and effective for treating advanced breast cancer in everyday medical practice.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only includes patients already prescribed the drug, which may limit generalizability.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••